Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...

Please provide your email address to receive an email when new articles are posted on . Understanding drug survival is important for clinical prescribing and long-term disease control. Bimekizumab has ...

The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.

Annual Meeting, James Song, MD, chief medical officer and director of clinical research, Frontier Dermatology, outlines maj ...

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic ...

A simulated analysis in psoriasis highlights divergent patient and payer incentives and inconsistent coverage strategies behind barriers to phototherapy uptake.

Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas ...

Despite a wide range of topical and systemic treatment options, there is still no cure for psoriasis. But the need for safe and effective therapies, along with an improved understanding of the ...

Biologic and conventional therapies were associated with comparable rates of cancer progression and recurrence among patients with psoriasis who have active cancer or who have had cancer within 5 ...